Merck Serono, Mersana Therapeutics collaboratively develop next-generation antibody drug conjugates

Merck Serono, Mersana to develop antibody-drug conjugates

9:39 AM, 24th June 2014
Merck Serono, Mersana Therapeutics business news

DARMSTADT, GERMANY: Merck Serono, the biopharmaceutical division of Merck, and Mersana Therapeutics, Inc, announced an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells which could lead to higher drug levels at the tumor site.

Mersana and Merck Serono will leverage Mersana’s Fleximer technology to generate ADCs for multiple undisclosed targets. Both parties have agreed to test a variety of ADCs by utilizing Mersana’s platform technologies and several cytotoxic agents as conjugates. This agreement further underlines Merck Serono’s approach to employ a collaborative research and development model, creating strategic partnerships to drive innovation, being consciously agnostic of the source of potential novel assets, and technologies.

Under the agreement, Merck Serono will provide monoclonal antibodies to Mersana, which will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities. Merck Serono will be responsible for clinical development and commercialization of any products under an exclusive license from Mersana. In addition to an upfront payment, Mersana is eligible to receive milestones plus royalties on worldwide net sales of products. Further financial details are not being disclosed.

“This new collaboration provides an exciting opportunity to expand our oncology drug discovery and development portfolio into the evolving ADC space. At Merck Serono, we have a long-standing commitment to improving oncology care, and we aim to deliver the best benefit possible to patients. Partnering with Mersana allows us to incorporate cutting-edge research and technical excellence to enrich our pipeline,” said Dr Andree Blaukat, Head of the Translational Innovation Platform Oncology, Merck Serono.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Chevron Phillips to construct polyethylene units in Old Ocean, US

THE WOODLANDS, US: Chevron Phillips Chemical Company LP (Chevron Phillips Chemical) held its second groundbreaking ceremony for its US Gulf Coast (USG ...

Read more
Researchers develop molecular computer using sugar

JENA, GERMANY: Researchers at Friedrich Schiller University Jena, Germany have developed the ‘sweetest computer in the world.’ The compute ...

Read more
AkzoNobel to invest in performance coatings business in China

AMSTERDAM, THE NETHERLANDS/SHANGHAI, CHINA: AkzoNobel is investing more than €6.5 million in its Songjiang site near Shanghai to expand an existi ...

Read more
Oxea completes construction of specialty esters plant in Nanjing, China

OBERHAUSEN, GERMANY: The chemical company Oxea’s specialty esters plant in Nanjing, China, is now mechanically complete and is currently in the ...

Read more
Making yarns from graphene oxide

PENNSYLVANIA, US: Researchers at Penn State and Shinshu University in Japan have developed a simple, scalable method of making graphene oxide (GO) fib ...

Read more
Bayer opens SeedGrowth Centre in Vietnam

MONHEIM, GERMANY: Bayer CropScience recently opened its new SeedGrowth Centre in Can Tho, Vietnam. This state-of-the-art facility aims to provide cust ...

Read more